DGX stock: buy or sell?

DGX stock price: $104.48 0.48% At close on November 19th, 2019

Updated on:
November 19th, 2019


Quest Diagnostics raised a slightly good 0.48% and closed at $104.48.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally.

Should I buy DGX stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to choose your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Quest Diagnostics stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean DGX will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Quest Diagnostics stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 15 ratings published for DGX stock in the last month.

Is DGX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-8Evercore ISIn/aBuy
2019-8-23Morgan Stanleyn/aOverweight
2019-7-24Morgan Stanleyn/aOverweight
2019-7-24JPMorgan Chase & Co.n/aNeutral
2019-7-24Credit Suisse Groupn/aNeutral
2019-7-24Canaccord Genuityn/aBuy
2019-7-15Goldman Sachs GroupNeutralSell
2019-4-25Morgan StanleyOverweightOverweight
2019-4-24UBS Groupn/aNeutral
2019-4-2Wolfe Researchn/aUnderperform
2019-4-2Jefferies Financial GroupHoldBuy
2019-3-18Credit Suisse GroupOutperformNeutral
2019-2-19Credit Suisse GroupOutperformOutperform

DGX stock analysis

Daily outlook

Quest Diagnostics shares raised 0.48% to $104.48 today.

Shares of Quest Diagnostics raised a slightly good 0.48% and closed at $104.48. In the last 6 days when DGX stock price broke up the SMA100d line, it gained $2.56 (2.51%).

DGX stock chart (daily)

Weekly outlook

Shares of Quest Diagnostics ended this week at $104.48 and stayed steady a neutral 0.25%.

Observing the weekly chart, DGX marked an uptrend of rising tops and rising bottoms. Since its last top by mid September at $107.43, price slid and bounced up back from $99.57. Breaking down under $99.57 would cancel the current uptrend and it might test lower supports. Note that $107.43 might act as a resistance line. Since mid June when SMA20w and SMA40w crossed up, DGX price gained $6.14 per share (6.24%). Since price and SMA40w lines crossed up late April, DGX climbed $19.60 (23.09%).

DGX stock chart (weekly)

DGX stock price history

DGX IPO was on December 17th, 1996 at $3.01 per share1. Since then, DGX stock surged a 3,371.10%, with an average of 153.20% per year. If you had invested $1,000 in DGX stock in 1996, it would worth $33,711.00 today.

1: Adjusted price after possible price splits or reverse-splits.

DGX stock historical price chart

DGX stock reached 52-week highs on September at $107.43, and all-time highs 2018-06-25 with a price of 112.17.

DGX stock price target is $104.90

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 13 price targets for DGX stock:
DGX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-8Evercore ISIReiteratesn/a$108.00-
2019-8-23Morgan StanleyRaises Target$111.00$121.009%
2019-7-24Morgan StanleyRaises Target$104.00$111.006.7%
2019-7-24JPMorgan Chase & Co.Raises Target$100.00$111.0011%
2019-7-24Credit Suisse GroupReiterates$99.00$105.006.1%
2019-7-24Canaccord GenuityRaises Target$108.00$112.003.7%
2019-7-15Goldman Sachs GroupDowngrades$90.00$85.00-5.6%
2019-4-25Morgan StanleyRaises Target$98.00$104.006.1%
2019-4-24UBS GroupRaises Target$91.00$99.008.8%
2019-4-24CitigroupRaises Target$93.00$102.009.7%
2019-3-18Credit Suisse GroupDowngradesn/a$91.00-
2019-2-19Credit Suisse GroupLowers Target$103.00$101.00-1.9%
(in average)$99.70$104.905.0%
The price forecast for Quest Diagnostics stock is $104.90, moving in a range between $121.00 and $85.00. In average, analysts' outlook on DGX price forecast is positive, increasing the forecast by a 5.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After publishing its last earnings report on February, Quest Diagnostics . Unfortunately, reported EPS is not yet available in our database.
DGX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual sales report draw a slightly fine gain of 1.74% to $7,531.00 million dollars. Improving that, its earnings margin (compared to sales) remained steady to 9.77%, that is $736.00 million.

DGX annual Sales and Income evolution
2013$7,150 M-$811 M11.3%-
2014$7,435 M3.99%$556 M7.5%-31.44%
2015$7,493 M0.78%$709 M9.5%27.52%
2016$7,515 M0.29%$645 M8.6%-9.03%
2017$7,402 M-1.50%$772 M10.4%19.69%
2018$7,531 M1.74%$736 M9.8%-4.66%

Quarterly financial results

Quest Diagnostics reported $1,839.00 million in sales for 2018-Q4, a -2.65% decline compared to previous quarter. Reported quarter income marked $127.00 million with a profit margin of 6.91%. Profit margin decreased a -4.37% compared to previous quarter when profit margin was 11.28%. When comparing turnover to same quarter last year, Quest Diagnostics sales marked a spooky slide and plunged a -15.33%. Looking back to recent quarterly results, Quest Diagnostics posted 2 positive quarters in a row.
DGX quarterly Sales and Income evolution
2017-Q2$1,940 M-$193 M9.9%-
2017-Q3$1,930 M-0.52%$160 M8.3%-17.10%
2017-Q4$2,172 M12.54%$254 M11.7%58.75%
2018-Q1$1,884 M-13.26%$177 M9.4%-30.31%
2018-Q2$1,919 M1.86%$219 M11.4%23.73%
2018-Q3$1,889 M-1.56%$213 M11.3%-2.74%
2018-Q4$1,839 M-2.65%$127 M6.9%-40.38%
2019-Q1$1,891 M2.83%$164 M8.7%29.13%

Quest Diagnostics ownership

When you are planning to invest in shares of a company, it's always worth to check its ownership structure.

Quest Diagnostics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.35% of all shares.

Bearish positions for DGX stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related stocks:

Market cap$14.1 B$135.5 M$16.6 B$2.5 B$53.5 M
Total shares134.7 M47.6 M97.1 M103.9 M5.5 M
Float shares134.0 M35.1 M96.5 M100.4 M4.7 M
  - Institutional holdings (%)91.5%75.8%94.1%77.2%58.5%
  - Insider holdings (%)0.4%7.4%0.6%8.1%7.8%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

DGX summary

Tuesday, November 19th, 2019
Day range$103.77 - $104.83
Previous close$103.98
Session gain0.48%
Average true range$1.31
50d mov avg$103.43
100d mov avg$102.32
200d mov avg$97.07
Daily pattern
Weekly pattern lb03a

Quest Diagnostics performance

To better understand Quest Diagnostics performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Quest Diagnostics against Enzo Biochem, Laboratory Corporation of America, NeoGenomics, Psychemedics and Qiagen in the following table:
DGXQuest Diagnostics3.35%7.66%14.29%
ENZEnzo Biochem-5.32%-11.76%-9.81%
LHLaboratory Corpor...3.24%2.66%5.90%

Quest Diagnostics competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for Quest Diagnostics. We picked 5 companies as Quest Diagnostics competitors as they are in the same industry or have similar market objectives.

Latest DGX stock news